Rong Ke
Overview
Explore the profile of Rong Ke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
358
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Maqsood I, Sareer S, Ur Rehman S, Hidayat A, Shah M, Awaz S, et al.
Poult Sci
. 2024 Dec;
104(1):104645.
PMID: 39689481
Food production needs to expand by 70% to keep up with the expected considerable increase in the world population by 2050. As a major source of high-quality protein, poultry products...
2.
Ke R, Kumar S, Singh S, Rana A, Rana B
Biochim Biophys Acta Rev Cancer
. 2024 Jul;
1879(5):189157.
PMID: 39032538
Mixed-lineage kinase 3 (MLK3) is a serine/threonine kinase of the MAPK Kinase kinase (MAP3K) family that plays critical roles in various biological processes, including cancer. Upon activation, MLK3 differentially activates...
3.
Ke R, Viswakarma N, Menhart M, Singh S, Kumar S, Srivastava P, et al.
Oncogene
. 2024 Jun;
43(30):2307-2324.
PMID: 38858590
Advanced hepatocellular carcinoma (HCC) is a lethal disease, with limited therapeutic options. Mixed Lineage Kinase 3 (MLK3) is a key regulator of liver diseases, although its role in HCC remains...
4.
Vishnoi K, Ke R, Viswakarma N, Srivastava P, Kumar S, Das S, et al.
Cell Death Dis
. 2022 Jul;
13(7):581.
PMID: 35789155
The incidence and mortality of hepatocellular carcinoma (HCC) are on a rise in the Western countries including US, attributed mostly to late detection. Sorafenib has been the first-line FDA-approved drug...
5.
Vishnoi K, Kumar S, Ke R, Rana A, Rana B
Curr Opin Pharmacol
. 2022 May;
64:102232.
PMID: 35526340
Hepatocellular carcinoma (HCC) is an inflammation-induced malignant disease of the liver. Abundant expression of immune checkpoint proteins has been reported in HCCs, which contribute to immune cell dysfunction and HCC...
6.
Principe D, Aissa A, Kumar S, Pham T, Underwood P, Nair R, et al.
Proc Natl Acad Sci U S A
. 2022 Apr;
119(18):e2200143119.
PMID: 35476525
There is currently no effective treatment for pancreatic ductal adenocarcinoma (PDAC). While palliative chemotherapy offers a survival benefit to most patients, nearly all will eventually progress on treatment and long-term...
7.
Vishnoi K, Ke R, Saini K, Viswakarma N, Nair R, Das S, et al.
Mol Pharmacol
. 2020 Nov;
99(1):1-16.
PMID: 33130557
Aberrant activation of Wnt/-catenin axis occurs in several gastrointestinal malignancies due to inactivating mutations of adenomatous polyposis coli (in colorectal cancer) or activating mutations of -catenin itself [in hepatocellular carcinoma...
8.
Zou J, Lei T, Guo P, Yu J, Xu Q, Luo Y, et al.
Mol Med Rep
. 2018 Dec;
19(2):759-770.
PMID: 30535440
Senescence is a result of cellular stress and is a potential mechanism for regulating cancer. As a member of the mitogen‑activated protein kinase family, ERK1/2 (extracellular signal‑regulated protein kinase) has...
9.
Maqsood I, Bukhari S, Ejaz R, Kausar S, Abbas M, Ali B, et al.
J Agric Food Chem
. 2018 Dec;
67(1):5-12.
PMID: 30520629
Sufficient statistics knowledge is crucial for the correct design of a research plan. The elucidations of results are interpretive only if appropriate statistical methods are applied. Statistical strategies are a...
10.
Ke R, Vishnoi K, Viswakarma N, Santha S, Das S, Rana A, et al.
Sci Rep
. 2018 Apr;
8(1):5521.
PMID: 29615720
Our previous studies indicated that combination of Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and PPARγ ligand Troglitazone (TZD), can induce significant apoptosis in various TRAIL-resistant prostate and hepatocellular carcinoma (HCC)...